Would you offer a different ALK inhibitor to a patient receiving alectinib who had decompensation of liver function in the setting of preexisting cirrhosis?   

Short answer is yes. In the pivotal phase III studies that compared alectinib, brigatinib, and lorlatinib to crizotinib in the first line setting (Peters et al., PMID 28586279, Camidge et al., PMID 30280657, Shaw et al., PMID 33207094 respectively), the risk of hepatic dysfunction (defined by increa...